Michael Petusky

Q: What is Michael Petusky's success rate?

Michael Petusky currently has a success rate of 96.91036072639896.

Q: What is the average return of Michael Petusky's calls?

Their stock ratings have generated an average return of 22.779976108019486.

Barrington Research | Healthcare

Michael Petusky is an analyst from Barrington Research specializing in the Healthcare sector. Ranked #1069 out of 4771 analysts, they have issued 62 stock ratings with a success rate of 96.91% and an average return of 22.78%.

Michael Petusky has a well-established track record, with 62 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 96.91% and an average return of 22.78%, underscoring their expertise and ability to identify winning opportunities for investors.

#1069

Out of 4771

Total Ratings

+96.91%

Success Rate

+22.78%

Average Return

Recent Ratings Analysis

HAE

Buy

Aug 19, 2026

Target

$118.00

Current

$101.06

Performance

-6.78%

Michael Petusky rated HAE as Outperform on Aug 19, 2026, setting a price target of 118. The stock has underperformed, dropping 6.78% despite the bullish target of 118.

OFIX

Buy

Jul 06, 2026

Target

$17.00

Current

$8.69

Performance

-24.89%

On Jul 06, 2026, OFIX was given a Outperform rating by Michael Petusky, with a target price of 17. Despite the Buy call, shares fell from 8.69 to 8.69, challenging the optimistic stance.

BVS

Buy

Jun 30, 2026

Target

$14.00

Current

$13.06

Performance

38.35%

BVS received a Outperform rating from Michael Petusky on Jun 30, 2026, aiming for 14. Momentum has favored the Buy call, with shares climbing from 13.06 to 13.06, rewarding those who trusted the recommendation.

LFCR

Buy

Jun 16, 2026

Target

$6.50

Current

$4.09

Performance

-23.55%

On Jun 16, 2026, Michael Petusky published a Outperform outlook on LFCR, with a target of 6.5. Market action contradicted the Buy thesis, as shares slipped to 4.09.

LMAT

Buy

Jun 03, 2026

Target

$120.00

Current

$78.80

Performance

-14.01%

Michael Petusky on Jun 03, 2026 assigned LMAT a Outperform rating, with a price target of 120. The call has struggled to gain traction, with shares losing 14.01%.

USPH

Buy

May 13, 2026

Target

$90.00

Current

$77.71

Performance

29.22%

On May 13, 2026, Michael Petusky reaffirmed USPH with a Outperform rating, targeting 90. The recommendation was supported by strong follow-through as the stock rose from 77.71 to 77.71.

OPCH

Buy

May 01, 2026

Target

$32.00

Current

$23.63

Performance

—

OPCH was rated Outperform by Michael Petusky on May 01, 2026, with a price objective of 32. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

MMSI

Buy

Apr 20, 2026

Target

$107.00

Current

$86.47

Performance

23.90%

On Apr 20, 2026, Michael Petusky initiated coverage on MMSI with a Outperform rating and target of 107. The stock’s climb of 23.90% since the call highlights the foresight in the rating.

OPK

Buy

Mar 02, 2026

Target

$2.25

Current

$1.49

Performance

20.16%

Michael Petusky issued a Outperform recommendation for OPK on Mar 02, 2026, price target set at 2.25. Investors following the Buy call captured upside momentum, with shares now at 1.49.

XRAY

Buy

Mar 02, 2026

Target

$17.00

Current

$10.50

Performance

-26.62%

On Mar 02, 2026, XRAY was evaluated by Michael Petusky, who gave a Outperform rating and target of 17. Investors saw limited payoff as shares fell short of the 17 target.

ANIK

Buy

Feb 27, 2026

Target

$17.00

Current

$20.99

Performance

46.17%

Michael Petusky rated ANIK as Outperform on Feb 27, 2026, setting a price target of 17. The call has proven timely, with shares rising 46.17% toward the price target of 17.

HSIC

Buy

Feb 25, 2026

Target

$97.00

Current

$87.30

Performance

6.58%

On Feb 25, 2026, HSIC was given a Outperform rating by Michael Petusky, with a target price of 97. The stock rallied 6.58% after the rating, narrowing the gap to the target of 97 and validating the bullish stance.

VRME

Buy

Jan 06, 2026

Target

$1.50

Current

$0.62

Performance

-40.86%

VRME received a Outperform rating from Michael Petusky on Jan 06, 2026, aiming for 1.5. The rating hasn’t played out as hoped, with the stock trading 40.86% below expectations.

SRDX

Sell

Nov 14, 2025

Target

—

Current

$42.98

Performance

3.29%

On Nov 14, 2025, Michael Petusky published a Underperform outlook on SRDX, with a target of null. The rating remains inconclusive as the market consolidates near 42.98.

MODV

Buy

Mar 07, 2025

Target

$6.00

Current

$0.43

Performance

-84.29%

Michael Petusky on Mar 07, 2025 assigned MODV a Outperform rating, with a price target of 6. The call has struggled to gain traction, with shares losing 84.29%.

Frequency Asked Questions

Who is Michael Petusky?

Michael Petusky is an analyst from Barrington Research specializing in the Healthcare sector.

What is Michael Petusky's success rate?

Michael Petusky currently has a success rate of +96.91%.

How many ratings has Michael Petusky issued?

Michael Petusky has issued 62 stock ratings so far.

What is the average return of Michael Petusky's calls?

Their stock ratings have generated an average return of +22.78%.

What is Michael Petusky's ranking?

Michael Petusky is ranked #1069 out of 4771 analysts.

What types of ratings does Michael Petusky give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Michael Petusky?

You can follow Michael Petusky by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Michael Petusky?

Their latest rating was a Buy on HAE issued on 2026-08-19.